LRP6 and coronary artery disorder: Reduced plasma levels of Wnt1 and elevated levels of LRP6 antagonists have been reproducibly associated with the risk for CAD in patients with early onset CAD, diabetes, and hyperlipidemia in several large clinical studies [8,47].